Company profile

Veru Inc.

Pipeline2 assets

EnobosarmVERU-024 / GTx-024 / Ostarine
SabizabulinVERU-111

Latest news7 items

Jul 7, 2026

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

May 13, 2026

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Interim Data • Phase 2Interim analysis Wed, Mar 31, 2027, 6:30 AM EDT

May 6, 2026

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Mar 9, 2026

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Trial Start • Phase 2

Feb 19, 2026

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Feb 4, 2026

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th